Trials / Completed
CompletedNCT02899104
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
Current Management, Treatment Patterns and Outcomes of Metastatic Castrate Resistant Prostate Cancer Patients Treated With Radium-223
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
Detailed description
This is a chart review of 200 Xofigo patients to describe sequencing and characterize clinical parameters and patient determinants that drive physician decision making.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xofigo (Radium-223 dichloride, BAY88-8223) | Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. |
Timeline
- Start date
- 2017-06-15
- Primary completion
- 2019-03-31
- Completion
- 2019-03-31
- First posted
- 2016-09-14
- Last updated
- 2020-03-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02899104. Inclusion in this directory is not an endorsement.